 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Allogene Therapeutics participates in a conference call with JPMorgan

Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T Cells Demonstration of Dagger Technology to Engineer CAR T cells to Selectively Eliminate...

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T  Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

This price move could be a signal that ALLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

Allogene Therapeutics (ALLO, $3.51) price may climb as it broke lower Bollinger Band on Sep 25, 2023

Allogene Therapeutics, Inc. (NASDAQ:ALLO  Get Free Report) shares traded down 3.8% on Monday after JPMorgan Chase  Co. lowered their price target on the stock from $11.00 to $9.00...

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 3.8% on Analyst Downgrade

Allogene Therapeutics price target lowered to $9 from $11 at JPMorgan

Allogene Therapeutics, Inc. (NASDAQ:ALLO  Get Free Report)s share price dropped 3.8% during trading on Monday after JPMorgan Chase  Co. lowered their price target on the stock from...

Allogene Therapeutics (NASDAQ:ALLO) Trading Down 3.8% Following Analyst Downgrade

This is a Bearish indicator signaling ALLO's price could decline from here. Traders may explore shorting the stock or put options...

Allogene Therapeutics (ALLO, $3.65) Moving Average Convergence Divergence (MACD) Histogram turned negative on September 22, 2023

Nordea Investment Management AB increased its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO  Free Report) by 20.1% in the 2nd quarter, according to the company in its most recent Form...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Holdings Increased by Nordea Investment Management AB

This price move could be a signal that ALLO may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Allogene Therapeutics (ALLO, $4.11) price may drop as it broke higher Bollinger Band on Sep 06, 2023

Citigroup Inc. raised its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO  Free Report) by 61.3% in the 1st quarter, according to its most recent 13F filing with the Securities and...

Citigroup Inc. Grows Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Watchers	2,757
52-Wk Low	$3.08
52-Wk High	$12.21

Market Cap	$531.37M
Volume (M)	2.86M
52-Wk High	$12.21
52-Wk Low	$3.08

Current Price	$3.17
Prev Close	$3.41
Open	$3.44
Dividend Yield	0.00%
50-Day Moving Average	$4.13
Beta	1.48
Avg. Volume	2M
PE Ratio	-1.29

52-Week High	$12.21
52-Week Low	$3.08
Market Capitalization	$531.37M
EPS	-$2.45
Price to Book	0.85
Revenue Per Employee	$531.86
Enterprise Value/EBITDA	-0.98

ALLO Allogene Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals